• Explore /
  • Poster
  • / Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation.

Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation.

Abstract Poster

Authors

Kathleen Moore

Kathleen N. Moore

University of Oklahoma Health Sciences Center, Oklahoma City, OK

Kathleen N. Moore , Charles Dresher , Joyce Liu , David M. O'Malley , Edward Wenge Wang , Judy Sing-Zan Wang , Vivek Subbiah , Breelyn A. Wilky , Guojun Yuan , Christopher D Dupont , Ana M Gonzalez , David Savitsky , Sara Coulter , Olga Shebanova , Ed Dow , Igor Proscurshim , Jennifer Buell , Robert Benjamin Stein , Hagop Youssoufian

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT03104699

Citation

J Clin Oncol 36, 2018 (suppl; abstr 3086)

DOI

10.1200/JCO.2018.36.15_suppl.3086

Abstract #

3086

Poster Bd #

300

Abstract Disclosures

Similar Posters

First Author: Melissa Lynne Johnson

First Author: Osama E. Rahma

First Author: Breelyn A. Wilky

Poster

2016 ASCO Annual Meeting

A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors.

A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors.

First Author: Aung Naing